The test, called CAPP-Seq, is a refinement of approaches that already exist to measure the level of DNA of the tumor in the patients bloodstream.
The detection of many types of cancer may soon be as easy as a simple blood test, according to a new study.
The blood test, developed by researchers at the Stanford University School of medicine, also can be used to “keep an eye on the amount of cancer in the body of the patient,” said the researchers, in addition to measuring their response to various treatments.
The test, called CAPP-Seq or Personalized Cancer Profiling by deep Sequencing, is a refinement of approaches that already exist to measure the level of tumor DNA in blood flow of patients, according to the study.
The new method can be “accurately identifying about 50 percent of people who studied with lung cancer stage-1 and all patients with advanced cancer,” according to the researchers.
Other parties which are not involved in this study hope.
“I think this is an important progress in this area,” said Dr. Abhijit Patel of the Yale Cancer Center and Smilow Cancer Hospital, where he researched similar.
“The goal is to detect very small tumor tumor-early stage.”
Patel said one of the major breakthroughs in this test is the ability to monitor changes in DNA mutations in cancer patients who have received treatment and may develop a resistance to certain drugs.
He also said that tests were likely will not give false positive results due to the “DNA mutations in cancer will most likely not be found in healthy people.”